(Montreal, February 15, 2016) Baylis Medical’s new streamlined transseptal system, licensed in Canada, comprised of a radiofrequency active pigtail guidewire and a steerable sheath, brings new possibilities to patients suffering from heart failure.
Dr. Jaimie Manlucu, treating physician, CANet Investigator, and member of the Arrhythmia Service at London Health Sciences in London, Ontario noted that a significant number of heart failure patients who are candidates for cardiac resynchronization therapy (CRT) often have suboptimal outcomes with conventional implant techniques. Placing CRT pacing wires into the left heart through the atrial septum is a promising alternative approach, but can be challenging without dedicated tools.
“This innovative transseptal system from Baylis Medical is the first commercially available apparatus that optimizes transseptal access from an alternate superior approach,” said Dr. Manlucu. “Streamlining the transseptal aspect of the implant procedure allows us to provide this therapy in a reliably safe and efficient way.”
“We are pleased to have developed this streamlined access method to the left atrium that enables physicians to deliver their therapies.” said Kris Shah, president of Baylis Medical. “Access to CANet’s leading-edge network of investigators allows us to validate our therapies and move them to the market – and bring relief to patients, faster.”
“Partnerships with Canadian companies, like Baylis Medical, are integral to developing and commercializing potentially lifesaving therapies,” said Dr. Anthony Tang, CEO and Scientific Director of CANet. “By working together we will develop cutting edge technologies and become a powerful engine of innovation for the arrhythmia field.”
These new devices developed and manufactured by Baylis Medical in Ontario, Canada were made possible in part by a repayable contribution through the Federal Economic Development Agency for Southern Ontario’s Advanced Manufacturing Fund.
The Cardiac Arrhythmia Network of Canada is a not-for-profit organization dedicated to transforming Canada’s arrhythmia health care system through integrated trans-disciplinary research and development. The network’s strategy is to invent, prove, and implement innovative solutions to enable patients to take ownership and co-manage their arrhythmia health. CANet is funded by the federal government's Networks of Centres of Excellence (NCE), Canada's flagship science and technology program.
About Baylis Medical Company:
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (UK). For more information, visit www.baylismedical.com.
Media Contact Person:
© Copyright Baylis Medical Company Inc., 2016. Baylis Medical Company Inc. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries. Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions, and instructions for use.
CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.
Baylis Medical Company Inc.
Copyright © 2016 CANet